Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT06598800. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-T187, an EGFR×MET Trispecific Antibody, Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
Study identification
- NCT ID
- NCT06598800
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 87 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 17, 2024
- Primary completion
- Sep 29, 2028
- Completion
- Sep 29, 2028
- Last update posted
- Mar 11, 2026
2024 – 2028
United States locations
- U.S. sites
- 4
- U.S. states
- 4
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Hackensack University Medical Center | Hackensack | New Jersey | 07601-1915 | Recruiting |
| The University of Texas Md Anderson Cancer Center | Houston | Texas | 77030-4009 | Recruiting |
| Next Virginia | Fairfax | Virginia | 22031 | Recruiting |
| Washington University, St Louis, Division of Oncology | Madison | Wisconsin | 53708-8056 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
Recently updated Advanced Solid Tumor trials
Other public records listing Advanced Solid Tumor. Sorted by last update posted; newest first. Not a recommendation.
- NCT06233942: Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Recruiting
- NCT06561685: A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors Recruiting
- NCT05245500: Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion Recruiting
- NCT06577987: Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies Active, not recruiting
- NCT06803680: A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors Recruiting
- NCT04855656: Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06598800, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 11, 2026 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06598800 live on ClinicalTrials.gov.